Optical coherence tomography (OCT) system developer Optovue (Fremont, CA) has received FDA approval for its AngioVue OCT angiography imaging system, which visualizes abnormal blood vessels in the retina noninvasively to help physicians determine an appropriate course of treatment. With the FDA clearance, the system is now available commercially in the U.S.
Related: Optovue receives $30M in financing to help market OCT angiography technology
The AngioVue system provides physicians with a noninvasive, dyeless technique for quickly visualizing the presence or absence of flow in the blood vessels. This enables assessment of new information from the microvasculature and perfusion in ocular diseases with unprecedented detail.
Using light rays to form detailed 3D images of the retina, physicians are able to quickly visualize blood vessels. In <3 s, the system acquires a single image that complements the current angiography imaging standard, fluorescein angiography (FA), but without dye injections that often obscure the target anatomy and can lead to side effects and other complications associated with dye-based, invasive procedures.
For more information, please visit www.optovue.com.